drug_type
RELEVANT_DRUG
intervention_type
Biologic drug (bispecific monoclonal antibody)
drug_description
Subcutaneous bispecific T-cell–redirecting monoclonal antibody (anti-BCMA×CD3) that binds BCMA on malignant plasma cells and CD3 on T cells to activate and redirect T-cell cytotoxicity against myeloma cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Teclistamab
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
Bispecific anti-BCMA×CD3 monoclonal antibody that binds BCMA on myeloma cells and CD3 on T cells, bringing them into proximity to activate and redirect T-cell cytotoxicity for targeted lysis of BCMA-expressing plasma cells.
drug_name
Teclistamab (Tecvayli)
nct_id_drug_ref
NCT06465316